AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16133387 — intervention group
Group type: COMPARATOR
Intervention: Cs correction
Number of subjects: 122
Study 11844897 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 666
Study 11844897 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid 900 mg and metoclopramide 10 mg
Number of subjects: 666
Study 10417049 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha2B (5.0 MU three times a week for 1 year)
Number of subjects: 96
Study 10417049 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group did not receive IFN)
Number of subjects: 96
Study 7588672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 micrograms kg‐1 min‐1 of PGE1
Number of subjects: 45
Study 7588672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 microgram kg‐1 min‐1 of PGE1
Number of subjects: 45
Study 7588672 — intervention group
Group type: COMPARATOR
Intervention: Control (no PGE1)
Number of subjects: 45
Study 2314351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of prostaglandin E1
Number of subjects: 0
Study 2314351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of buflomedil
Number of subjects: 0
Study 2314351 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no infusion)
Number of subjects: 0
Study 476231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine-beta-hydroxylase inhibitor (fusaric acid) combined with L-dopa (500 mg)
Number of subjects: 0
Study 476231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 476231 — intervention group
Group type: COMPARATOR
Intervention: L-dopa alone
Number of subjects: 0
Study 30883052 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal-flow pump
Number of subjects: 1028
Study 30883052 — intervention group
Group type: COMPARATOR
Intervention: Axial-flow pump
Number of subjects: 1028
Study 29190761 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minutes standing every 20 minutes
Number of subjects: 10
Study 29190761 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minutes walking every hour
Number of subjects: 10
Study 29190761 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes standing every hour
Number of subjects: 10
Study 29190761 — intervention group
Group type: COMPARATOR
Intervention: Prolonged sitting control condition
Number of subjects: 10
Study 25602889 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVSRR plus savings-led microfinance intervention (n=57)
Number of subjects: 107
Study 25602889 — intervention group
Group type: COMPARATOR
Intervention: HIVSRR alone (n=50)
Number of subjects: 107
Study 23948862 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher RBC levels of total n‐3 LC‐PUFA and DHA in patients who developed POAF
Number of subjects: 125
Study 23948862 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative interleukin‐6 levels
Number of subjects: 125
Study 23948862 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory mediators
Number of subjects: 125
Study 23948862 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 LC‐PUFA levels in RBC membranes measured prior to CABG and on postoperative day 3
Number of subjects: 125
Study 21208928 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal tuberculosis (TB) during pregnancy and up to 12 months after delivery
Number of subjects: 783
Study 21208928 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal TB
Number of subjects: 783
Study 19412843 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning irradiation (08:00-11:00 h)
Number of subjects: 212
Study 19412843 — intervention group
Group type: COMPARATOR
Intervention: Evening irradiation (15:00-18:00 h)
Number of subjects: 212
Study 17291359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 0
Study 17291359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15562885 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg daily for 4 days)
Number of subjects: 18
Study 15562885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine hydrochloride (10 mg daily for 4 days)
Number of subjects: 18
Study 15562885 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Loratadine vs Cetirizine hydrochloride
Number of subjects: 18
Study 11213011 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy via culdotomy (Group B)
Number of subjects: 79
Study 11213011 — intervention group
Group type: COMPARATOR
Intervention: Vaginal cystectomy without laparoscopy (Group A)
Number of subjects: 79
Study 9669460 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 21
Study 9669460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 21
Study 7804490 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-initiated discussion on advance directives (AD)
Number of subjects: 100
Study 7804490 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-initiated discussion on health promotion issues
Number of subjects: 100
Study 3044872 — intervention group
Group type: COMPARATOR
Intervention: Codergocrine mesylate, increasing dosage over 12 weeks
Number of subjects: 40
Study 3044872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29634641 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium difficulty level
Number of subjects: 36
Study 29634641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard difficulty level
Number of subjects: 36
Study 29634641 — intervention group
Group type: COMPARATOR
Intervention: Low difficulty level
Number of subjects: 36
Study 28605603 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 7637
Study 28605603 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 7637
Study 25088249 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional conformal radiotherapy followed by 2-3 series of TACE (Group A)
Number of subjects: 63
Study 25088249 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolisation (TACE) alone (Group B)
Number of subjects: 63
Study 25125055 — intervention group
Group type: EXPERIMENTAL
Intervention: Rop/Dx (ropivacaine with dexamethasone)
Number of subjects: 80
Study 25125055 — intervention group
Group type: COMPARATOR
Intervention: Rop (ropivacaine alone)
Number of subjects: 80
Study 19815346 — intervention group
Group type: EXPERIMENTAL
Intervention: Task persistence
Number of subjects: 241
Study 19815346 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 241
Study 18311126 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Number of subjects: 9
Study 18311126 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study 16153780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1000mg)
Number of subjects: 60
Study 16153780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12816696 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC triple therapy
Number of subjects: 552
Study 12816696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study 10098571 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure
Number of subjects: 248
Study 10098571 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture/Discussion
Number of subjects: 248
Study 10098571 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Decision Support
Number of subjects: 248
Study 10098571 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS Tools (all formats)
Number of subjects: 248
Study 10098571 — intervention group
Group type: EXPERIMENTAL
Intervention: More Intensive Interventions
Number of subjects: 248
Study 9345431 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian MS patients
Number of subjects: 0
Study 9345431 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian MS patients with prominent optic neuritis (PON)
Number of subjects: 0
Study 9345431 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 1817628 — intervention group
Group type: COMPARATOR
Intervention: Morphine 3 mg
Number of subjects: 28
Study 1817628 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 75 micrograms
Number of subjects: 28
Study 1817628 — intervention group
Group type: COMPARATOR
Intervention: Morphine 3 mg plus Clonidine 75 micrograms
Number of subjects: 28
Study 6115999 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 23582
Study 6115999 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 23582
Study 6115999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23582
Study 31842036 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1.5% Azithromycin (AZ) administered as a unit dose
Number of subjects: 85
Study 31842036 — intervention group
Group type: COMPARATOR
Intervention: Control group (no topical AZ)
Number of subjects: 85
Study 31823650 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT) 15 g extract granule daily for 4 weeks
Number of subjects: 0
Study 31823650 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT)
Number of subjects: 0
Study 28292739 — intervention group
Group type: EXPERIMENTAL
Intervention: Website with product-specific information
Number of subjects: 672
Study 28292739 — intervention group
Group type: EXPERIMENTAL
Intervention: Website without product-specific information
Number of subjects: 672
Study 28292739 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to the website)
Number of subjects: 672
Study 28292739 — intervention group
Group type: EXPERIMENTAL
Intervention: Website use
Number of subjects: 672
Study 28292739 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of the website
Number of subjects: 672
Study 25944023 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-reduction intervention (SRI)
Number of subjects: 0
Study 25944023 — intervention group
Group type: COMPARATOR
Intervention: Exercise- and diet-advice arm (EDA)
Number of subjects: 0
Study 23359067 — intervention group
Group type: EXPERIMENTAL
Intervention: HM10460A 45 μg/kg
Number of subjects: 40
Study 23359067 — intervention group
Group type: EXPERIMENTAL
Intervention: HM10460A 135 μg/kg
Number of subjects: 40
Study 23359067 — intervention group
Group type: EXPERIMENTAL
Intervention: HM10460A 350 μg/kg
Number of subjects: 40
Study 23359067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21323679 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (peak breath alcohol concentration of 0.11 ± 0.01 g%)
Number of subjects: 93
Study 21323679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 17728695 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine, 0.65 g kg(‐1) daily for 7 days
Number of subjects: 76
Study 17728695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glutamine)
Number of subjects: 76
Study 16720935 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body-vibration (WBV) treatment, 5 series of 60 seconds each
Number of subjects: 68
Study 16720935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no WBV treatment)
Number of subjects: 68
Study 16720935 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body-vibration (WBV) treatment (cross-over design)
Number of subjects: 68
Study 16720935 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body-vibration (WBV) treatment
Number of subjects: 68
Study 15533869 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NT-proBNP levels >250 ng/L
Number of subjects: 1791
Study 15533869 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP in troponin T-negative patients
Number of subjects: 1791
Study 15533869 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical stabilization without refractory ischemia
Number of subjects: 1791
Study 15533869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of rapid decline in NT-proBNP levels (< or =250 ng/L)
Number of subjects: 1791
Study 15533869 — intervention group
Group type: EXPERIMENTAL
Intervention: Rise in NT-proBNP levels over 72 hours to >250 ng/L
Number of subjects: 1791
Study 11731689 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours bedrest
Number of subjects: 354
Study 11731689 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 hours bedrest
Number of subjects: 354
Study 11731689 — intervention group
Group type: COMPARATOR
Intervention: 6 hours bedrest
Number of subjects: 354
Study 9231658 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycemia of 3.9 mmol/l
Number of subjects: 8
Study 9231658 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycemia of 3.3 mmol/l
Number of subjects: 8
Study 9231658 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycemia of 2.9 mmol/l
Number of subjects: 8
Study 8029784 — intervention group
Group type: EXPERIMENTAL
Intervention: Melipramine (3 x 2 coated tablet) given in 60‐mg daily doses for 2 and 4 weeks
Number of subjects: 50
Study 8029784 — intervention group
Group type: EXPERIMENTAL
Intervention: Melipramine (3 x 2 coated tablet) given in 60‐mg daily doses
Number of subjects: 50
Study 3323258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg at bedtime for four days prior to chloroquine administration)
Number of subjects: 10
Study 29402789 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine N-Butylbromide (20 mg)
Number of subjects: 60
Study 29402789 — intervention group
Group type: COMPARATOR
Intervention: Sodium Chloride (0.9%)
Number of subjects: 60
Study 26797664 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered computer therapy for apraxia of speech
Number of subjects: 50
Study 26797664 — intervention group
Group type: COMPARATOR
Intervention: Visuospatial sham program
Number of subjects: 50
Study 24400719 — intervention group
Group type: COMPARATOR
Intervention: Monofocal aspheric lens ZA9003 (control group)
Number of subjects: 143
Study 24400719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid diffractive MIOLs (ZMA00)
Number of subjects: 143
Study 24400719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid spherical SN60D3
Number of subjects: 143
Study 24400719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid aspheric SN6AD1
Number of subjects: 143
Study 24400719 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive spherical NXG1
Number of subjects: 143
Study 22529257 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT) with fluorouracil 800 mg/m(2)/d IV infusion on days 1-4 and 29-32, and cisplatin 80 mg/m(2) IV on days 1 and 29, followed by concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and standard-dose boost (SD) of 15 Gy.
Number of subjects: 307
Study 22529257 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT) with fluorouracil and cisplatin, followed by concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and high-dose boost (HD) of 20-25 Gy.
Number of subjects: 307
Study 22529257 — intervention group
Group type: COMPARATOR
Intervention: Concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and standard-dose boost (SD) of 15 Gy (reference arm).
Number of subjects: 307
Study 22529257 — intervention group
Group type: COMPARATOR
Intervention: Concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and high-dose boost (HD) of 20-25 Gy.
Number of subjects: 307
Study 22529257 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy (ICT) effect comparison between groups A and B versus C and D.
Number of subjects: 307
Study 22529257 — intervention group
Group type: COMPARATOR
Intervention: Radiation dose effect comparison between groups A and C versus B and D.
Number of subjects: 307
Study 20534421 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEpo) - 3 consecutive intravenous doses (24,000 IU)
Number of subjects: 20
Study 20534421 — intervention group
Group type: COMPARATOR
Intervention: Control group (no erythropoietin treatment)
Number of subjects: 20
Study 17313499 — intervention group
Group type: COMPARATOR
Intervention: Standard triple eradication therapy (esomeprazole, clarithromycin, amoxicillin)
Number of subjects: 206
Study 17313499 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified eradication therapy (standard triple therapy plus bovine lactoferrin and probiotics)
Number of subjects: 206
Study 15252435 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for homecare nurses (Power Over Pain)
Number of subjects: 202
Study 15252435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 202
Study 11287377 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise (gait)
Number of subjects: 13
Study 9565410 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive seminar for physicians
Number of subjects: 637
Study 9565410 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 637
Study 3069881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 21
Study 29673831 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypovitaminosis D defined as serum 25-hydroxyvitamin D concentration (25OHD) ≤30 ng/mL
Number of subjects: 744
Study 29673831 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25OHD concentration
Number of subjects: 744
Study 29673831 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypovitaminosis D ≤ 30 ng/mL
Number of subjects: 744
Study 27083763 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus multivitamins (20 mg elemental zinc, vitamin A 1000 IU, vitamin D 200 IU, B1 10 mg, B2 3 mg, B6 1 mg, B12 10 μg, nicotinamide 40 mg)
Number of subjects: 140
Study 27083763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 24945737 — intervention group
Group type: EXPERIMENTAL
Intervention: silymarin (420 mg/day)
Number of subjects: 0
Study 24945737 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 24945737 — intervention group
Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 0
Study 22257240 — intervention group
Group type: EXPERIMENTAL
Intervention: GreenLight HPS™ 120-W laser photovaporization of the prostate (PVP)
Number of subjects: 20
Study 22257240 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 20
Study 20739647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (flexible-dose up to 200 mg)
Number of subjects: 38
Study 20739647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 20739647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 38
Study 18295700 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidewire
Number of subjects: 0
Study 18295700 — intervention group
Group type: EXPERIMENTAL
Intervention: HiWire
Number of subjects: 0
Study 15718040 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary fibroblast cultures from AD patients
Number of subjects: 10
Study 15718040 — intervention group
Group type: COMPARATOR
Intervention: Aged individuals
Number of subjects: 10
Study 15718040 — intervention group
Group type: EXPERIMENTAL
Intervention: AD fibroblasts
Number of subjects: 10
Study 15718040 — intervention group
Group type: EXPERIMENTAL
Intervention: EAAT1 parameters
Number of subjects: 10
Study 15232334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 5 mg
Number of subjects: 270
Study 15232334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 20 mg
Number of subjects: 270
Study 15232334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 40 mg
Number of subjects: 270
Study 15232334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 11758326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2% lidocaine mixed with propofol)
Number of subjects: 40
Study 11758326 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1% propofol 20 ml with 2 ml of normal saline)
Number of subjects: 40
Study 9399233 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-training videotape on motor fluctuations
Number of subjects: 32
Study 9399233 — intervention group
Group type: COMPARATOR
Intervention: General patient educational material (control group)
Number of subjects: 32
Study 7706597 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day sugar added to meals
Number of subjects: 19
Study 7706597 — intervention group
Group type: COMPARATOR
Intervention: Diet similar to home diet
Number of subjects: 19
Study 7706597 — intervention group
Group type: COMPARATOR
Intervention: Diabetic hospital dietary regimen without added sugar
Number of subjects: 19
Study 3580232 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulphate 10.6‐38.5 mg kg‐1
Number of subjects: 30
Study 3580232 — intervention group
Group type: COMPARATOR
Intervention: No antidote (control group)
Number of subjects: 30
Study 31686590 — intervention group
Group type: COMPARATOR
Intervention: Advanced statistical modeling (LASSO, ridge regression, elastic nets, support vector machines, random forests) applied to baseline prognostic factors for disability progression.
Number of subjects: 1582
Study 31686590 — intervention group
Group type: COMPARATOR
Intervention: Advanced statistical modeling (various methods) for predicting disability progression.
Number of subjects: 1582
Study 31686590 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity analyses for different definitions of a combined endpoint.
Number of subjects: 1582
Study 30930355 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip trainer device (group P, n = 13)
Number of subjects: 39
Study 30930355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic toothbrush (group S, n = 13)
Number of subjects: 39
Study 30930355 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C, n = 13)
Number of subjects: 39
Study 29202535 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50mg subcutaneously every 4 weeks
Number of subjects: 25
Study 29202535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 29202535 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50mg from week 24 to week 48
Number of subjects: 25
Study 26700568 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week neuromuscular and quadriceps/hip strength training programme
Number of subjects: 48